Patheon Broadens Its Pharma Client Base With Mova Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Mova’s “excellent relationships with some of the largest pharmaceutical companies in the world,” including Merck, are a major attraction for Patheon, CEO Tedford says. The acquisition, valued at $350 mil., is expected to close in late December.